Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech conference presentation

Moderna intismeran melanoma data at ESMO 2026

Analysis based on 7 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026

Sentiment
15
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The acceptance of late-breaking Phase 3 melanoma data for a Presidential Symposium raises the visibility of Moderna's individualized neoantigen therapy program and could support sentiment toward MRNA shares ahead of the October readout. Merck also stands to benefit as co-developer, though the near-term market reaction likely hinges on the actual data presented rather than the abstract acceptance itself.

pharmaceuticals biotechnology healthcare

Moderna announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology Congress 2026, to be held October 23-27 in Madrid, Spain. The lead presentation, LBA1 INTerpath-001, is a Phase 3 study of intismeran autogene plus pembrolizumab versus pembrolizumab alone for adjuvant treatment of resected stage IIB-IV melanoma, selected for a Presidential Symposium on October 24. Two poster presentations cover adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma from a phase I study, and INTerpath-014, a Phase 3 study in completely resected high-risk stage I NSCLC. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. Moderna will host an investor webcast on October 24 at 7:00 PM CEST. Presenters include Georgina Long, David J. Pinato, and Charu Aggarwal.

70 Moderna announced abstracts accepted European Society for Medical Oncology
50 Merck & Co. jointly developed therapy Moderna
40 Moderna announced investor webcast
stock
Moderna is the central actor, announcing the ESMO abstract acceptances and hosting an investor webcast; positive Phase 3 melanoma data could materially support its oncology pipeline narrative and stock.
Importance 100.0 Sentiment 20.0
stock
Merck co-develops intismeran autogene with Moderna, so successful data would validate its mRNA oncology collaboration and pembrolizumab combination strategy.
Importance 70.0 Sentiment 10.0
ngo
ESMO hosts the congress where the data will be presented, gaining prominence from the late-breaking Presidential Symposium selection.
Importance 40.0 Sentiment 0.0
per
Long will present the Phase 3 INTerpath-001 melanoma data at the Presidential Symposium, lending scientific credibility.
Importance 15.0 Sentiment 0.0
cnt
The United States is home to Moderna and Merck and to presenter Charu Aggarwal, but plays no direct role in the event.
Importance 10.0 Sentiment 0.0
cnt
Spain hosts the ESMO Congress 2026 in Madrid, a minor logistical and reputational role.
Importance 10.0 Sentiment 0.0
per
Pinato will present the phase I pancreatic cancer poster on intismeran autogene plus FOLFIRINOX.
Importance 10.0 Sentiment 0.0
per
Aggarwal will present the INTerpath-014 trial-in-progress poster in early-stage NSCLC.
Importance 10.0 Sentiment 0.0
cnt
Australia is the base of presenter Georgina Long, a peripheral detail.
Importance 5.0 Sentiment 0.0
cnt
The United Kingdom is the base of presenter David J. Pinato, a peripheral detail.
Importance 5.0 Sentiment 0.0
Moderna related ↔ Merck & Co.
Moderna related ↔ United States
Moderna related ↔ Australia
Moderna related ↔ United Kingdom
United States related ↔ Spain
United States related ↔ Australia
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
Spain related ↔ Australia
Spain related ↔ United Kingdom
Australia allies ↔ United Kingdom Australia views the United Kingdom as a foundational strategic and economic ally, anchored by the AUKUS defense pact and
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.